JP2005514418A - カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用 - Google Patents

カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用 Download PDF

Info

Publication number
JP2005514418A
JP2005514418A JP2003557981A JP2003557981A JP2005514418A JP 2005514418 A JP2005514418 A JP 2005514418A JP 2003557981 A JP2003557981 A JP 2003557981A JP 2003557981 A JP2003557981 A JP 2003557981A JP 2005514418 A JP2005514418 A JP 2005514418A
Authority
JP
Japan
Prior art keywords
nitrogen
hydroxy
group
heterocycle
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003557981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514418A5 (enExample
Inventor
ジータ イェゲスネー,チャーカイ
マールバーニョシュ,エデ
ユーログディ,ラースロー
マグドルナ バツォーネー,テレク
デーネシュ,ラースロー
Original Assignee
ビオレックス クタトー エス フェイレストェー アールテー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0200109A external-priority patent/HUP0200109D0/hu
Priority claimed from HU0204362A external-priority patent/HUP0204362D0/hu
Application filed by ビオレックス クタトー エス フェイレストェー アールテー. filed Critical ビオレックス クタトー エス フェイレストェー アールテー.
Publication of JP2005514418A publication Critical patent/JP2005514418A/ja
Publication of JP2005514418A5 publication Critical patent/JP2005514418A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2003557981A 2002-01-11 2003-01-10 カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用 Pending JP2005514418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0200109A HUP0200109D0 (en) 2002-01-11 2002-01-11 Compounds having pharmaceutical activity
HU0204362A HUP0204362D0 (en) 2002-12-17 2002-12-17 Compounds having pharmaceutical activity
PCT/HU2003/000003 WO2003057664A1 (en) 2002-01-11 2003-01-10 Carboxamidine derivatives and their use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
JP2005514418A true JP2005514418A (ja) 2005-05-19
JP2005514418A5 JP2005514418A5 (enExample) 2006-03-02

Family

ID=90001534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003557981A Pending JP2005514418A (ja) 2002-01-11 2003-01-10 カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用

Country Status (17)

Country Link
US (5) US7384936B2 (enExample)
EP (1) EP1492763A1 (enExample)
JP (1) JP2005514418A (enExample)
KR (1) KR20040089102A (enExample)
CN (1) CN1615296A (enExample)
AU (1) AU2003202104B8 (enExample)
BR (1) BR0306778A (enExample)
CA (1) CA2471752A1 (enExample)
HR (1) HRP20040558A2 (enExample)
IL (1) IL162941A0 (enExample)
MX (1) MXPA04006716A (enExample)
NO (1) NO20043029L (enExample)
NZ (1) NZ533795A (enExample)
PL (1) PL371251A1 (enExample)
RS (1) RS60604A (enExample)
RU (1) RU2320330C2 (enExample)
WO (1) WO2003057664A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) * 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
DK2892540T3 (en) * 2012-09-06 2018-11-19 Mcpharma Biotech Inc TREATMENT OF DIARRES AND DRAWN DIARRES WITH RESISTANT POTATO STARCH
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
CN109069298B (zh) 2016-04-01 2021-08-10 3M创新有限公司 听力保护装置及形成其的方法
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
DE2651083A1 (de) 1976-11-09 1978-05-18 Hoechst Ag Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung
IT1110460B (it) 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
US4187220A (en) 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
EP0369944A1 (de) 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
HUT54347A (en) 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
GB9017351D0 (en) 1990-08-08 1990-09-19 Wellcome Found Medicaments for treatment of atherosclerosis
EP0495750A3 (en) 1991-01-14 1992-09-16 Ciba-Geigy Ag Heterocyclic hydroxylamine
US5334600A (en) 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
BR9407933A (pt) * 1993-11-01 1996-11-26 Japat Ltd Antagonistas de receptores de endotelina
CN1079789C (zh) * 1994-05-06 2002-02-27 拜奥列克斯研究发展公司 新的羟肟酸衍生物,包含它们的药物组合物及其制法
HU218480B (hu) 1995-06-15 2000-09-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP9702365A3 (en) * 1997-04-22 1999-09-28 Biorex Kutato Fejlesztoe Kft Application of hydroxilamin-derivatives, as well as process and composition for increase of weather extreme resistent by cultivated plants
HU226617B1 (en) 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
WO2003057664A1 (en) * 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
NO20043029L (no) 2004-10-11
RU2320330C2 (ru) 2008-03-27
RS60604A (sr) 2006-12-15
IL162941A0 (en) 2005-11-20
HRP20040558A2 (en) 2004-10-31
MXPA04006716A (es) 2004-11-10
BR0306778A (pt) 2004-12-28
US20080058323A1 (en) 2008-03-06
KR20040089102A (ko) 2004-10-20
EP1492763A1 (en) 2005-01-05
US7361655B2 (en) 2008-04-22
AU2003202104B8 (en) 2008-10-02
RU2004124378A (ru) 2005-04-20
US20090075993A1 (en) 2009-03-19
CA2471752A1 (en) 2003-07-17
US20090253690A1 (en) 2009-10-08
WO2003057664A1 (en) 2003-07-17
US7550457B2 (en) 2009-06-23
US7384936B2 (en) 2008-06-10
AU2003202104A1 (en) 2003-07-24
NZ533795A (en) 2006-03-31
US7691849B2 (en) 2010-04-06
US20050043295A1 (en) 2005-02-24
AU2003202104B2 (en) 2008-09-18
PL371251A1 (en) 2005-06-13
CN1615296A (zh) 2005-05-11
US20060058294A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
US7691849B2 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
US3900481A (en) Derivatives of pyrrolidine and piperidine
US6737425B1 (en) N,N-substituted cyclic amine derivatives
CA2787248C (en) Piperazine compound having a pgds inhibitory effect
JPH0317046A (ja) アリールオキシフエニルプロピルアミン、その製造方法及びその使用方法
WO1992000962A1 (en) Diphenylmethylpiperazine derivative
BRPI0110184B1 (pt) derivado de piridina-1-óxido, e processo para a sua transformação em compostos farmaceuticamente eficazes
EP0254623A1 (fr) Nouveaux dérivés amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procédés de préparation, médicaments les contenant, utiles notamment comme antalgiques
US4727072A (en) 3-alkoxy-2-aminopropylamines compositions and use as cardiovascular agents
TWI236469B (en) Diamine compound with condensed-ring groups
JPH04217955A (ja) 置換ベンズインドールイミン誘導体及びその製法
BG63305B1 (bg) Фармацевтични пиперазинови производни
JP3158638B2 (ja) 新規アミノフェノール誘導体及びその医薬用途
US4758563A (en) 3-alkoxy-2-aminopropyamines, cardiovascular compositions and use
JPS62212386A (ja) 2−ピリジルメチルベンズイミダゾ−ル誘導体
US3954776A (en) 1-[Methylated piperidino(and pyrrolidin-1-yl)]-3-(substituted phenoxy)-2propanols
ZA200404996B (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
TW403745B (en) Novel substituted -amidinobenzene derivative and pharmaceutical compositions thereof
HUP0402526A2 (hu) Vaszkuláris betegségek gyógyítására használható hidroxilaminszármazékok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JPS62108863A (ja) 2−ピリジル酢酸誘導体、その製法およびそれを含む医薬
UA77731C2 (en) Carboxaniidine derivatives and use thereof in the treatment of vascular diseases
RU2045521C1 (ru) Производные 1,2,4-триазолилтиоамидов
JPH03106873A (ja) 1―ピリジルフタラジン誘導体及びそれらを含有する血小板凝集抑制剤
JPH0253780A (ja) Δ↑2‐1,2,4‐トリアゾリン‐5‐オン誘導体、その製造法およびそれを有効成分とする抗潰瘍剤
JPH02202857A (ja) アミノアルコキシベンゼン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060110

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105